



EUROPEAN ASSOCIATION OF  
PHARMA BIOTECHNOLOGY



# Be part of a strong network!

## Newsletter December 2009

Dear EAPB member or friend,

End of the year – before starting into holidays - we provide some important news, reminders and requests you *must* know:

- The conference **Science to Market 2009** in Hanover was a great and interesting event achieving its objective to provide a suitable platform where researchers from academia and small biotech companies can find industrial partners. Well known scientists gave state of the art plenary lectures on highlights in the areas of antibody, stem cells, RNA therapies, diagnostics and biotechnological production processes. The conference book, abstracts, presentations (including the splendid key note of Ernst-Peter Fischer) you find [here](#).
- "European Biotechnology News" won't be our printed and sent members' journal. Many members are already subscribers and prefer to get additional the online version – we'll negotiate this with the publisher.
- EAPB offers a **new service for our members**: beside the job platform on EAPB website we want to start a **platform for press releases** to increase the visibility of our members in the European area. You are kindly invited to send your press releases to [managing.director@eapb.org](mailto:managing.director@eapb.org).
- The office of EAPB has moved from Berlin to Heidelberg

If you find this newsletter interesting, feel invited to send me your feedback comments, we are open for further development to provide maximal value to all EAPB members. Feel also cordially invited to send articles for the next newsletter which is announced for March 2010. We appreciate your collaboration and input!

I look forward to hearing from you and wish you a wonderful, contemplative and relaxing Christmas time and a vibrant start into 2010.

Yours sincerely,

**Marion Kronabel**

Managing Director EAPB

Enjoy reading this newsletter!

### **Content of this issue**

- ▶ Introductory remarks – wrap up of last activities ([S2M2009](#) / members journal / our office / new press service platform
- ▶ Science to Market 2010 – your opportunities

- ▶ New Special Interest Group  
Regulatory Aspects during Biopharmaceutical Development
- ▶ New Special Interest Group  
Regenerative Medicine

## Science to Market 2010 – Vienna, February 24 – 25, 2010

### Posttranslational Modification of Proteins, Consequences and Therapeutic Use

As a platform for European scientific research and biopharmaceutical industry the European Association of Pharma Biotechnology (EAPB) organizes the third conference 'Science to Market' which takes place in Vienna, February 24 – 25, 2010. EAPB's Partner is the Vienna Institute of Bio Technology (VIBT).

The goal of this European event is the promotion of collaborations between science and industry in the sector of pharmaceutical biotechnology to enhance the economical output of scientific research and direct them into marketable technologies and biopharmaceutical products. The two days conference focuses on innovative biopharmaceutical drug and diagnostic developments and novel technologies for the development and production of those products.

The **panel lectures** focus on posttranslational modifications.

The **key note** is about "Biopharmaceutical Manufacturing Trends" and will be presented by Rolf Werner, Boehringer Ingelheim.

The **posters and short presentations** get two sessions:

- "Novel therapeutics, vaccines and diagnostics"
- "Novel Technologies" (up- and downstream, drug formats, analytical tools)

**Deadline for posters' and abstracts' submission: February 8, 2010!**

**Sponsoring** would be welcome and highly appreciated.

Find all mentioned information in detail in the following documents:

[Conference Announcement](#)  
[Programme](#)  
[Poster Contribution Form](#)  
[Registration Form](#)  
[Sponsoring Opportunities](#).

---

## New Special Interest Group

### Current Regulatory Aspects during Biopharmaceutical Development

The new Special Interest Group intends to openly discuss between regulatory experts and industrial CMC experts the burden versus the benefits of the new philosophy and targets at giving in the end some guidance to the participants in the Working Group and outside (via white papers).

#### Organising Committee:

[Karoline Bechtold-Peters, Ph.D.](#), 1st Vice President EAPB, Biberach (GER)

Axel Wenzel, Ph.D., 2nd Vice President EAPB, Munich (GER)

---

# New Special Interest Group

## Regenerative Medicine

The new Special Interest Group has the goal to create a bridge and network between scientists working in the fields of regenerative medicine, stem cell biology and drug discovery. In 2010 the group intends to promote the discussion and dissemination of new information related to stem cells technology for non- and therapeutic applications addressing in this regard also questions relating to manufacturing and regulatory processes.

### Organising Committee:

Joachim Nöller, Ph.D., EAPB Board Member, Leipzig (GER)

**Both Special Interest Groups (SIGs) will be inaugurated in Vienna on February 23, 2010.**

The participation in the SIGs is free of charge but requires registration.

Find all mentioned information in detail in the following documents:

[Announcement for SIGs](#)

[Registration form](#)



EUROPEAN ASSOCIATION OF  
PHARMA BIOTECHNOLOGY

---

**EAPB** is the representative and central network to promote and develop Pharma Biotechnology in Europe, linking academia, industries and regulatory bodies.

Members are scientists (individual membership), companies, departments of companies and organisations from academia (corporate membership), but also industry, especially pharmaceutical industry and related sciences involved in pharma biotechnology.

### Editorial responsibility

EAPB assumes responsibility for content according to German media law. If you have any queries regarding the association or require any further information, do not hesitate to contact us.

European Association Pharma Biotechnology

Dr. Marion Kronabel, Managing Director

Email: [Dr. Marion Kronabel](mailto:Dr.Marion.Kronabel)